Skip to content
  • Sunday, 26 July 2026
  • 4:37 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Voro Therapeutics and Alloy Therapeutics Forge Strategic Partnership to Revolutionize Tumour-Selective T-Cell Engager Therapies
Pharmaceutical R&D

Voro Therapeutics and Alloy Therapeutics Forge Strategic Partnership to Revolutionize Tumour-Selective T-Cell Engager Therapies

Teuku Ryan Jun 20, 2026 0

Voro Therapeutics and Alloy Therapeutics have announced a significant strategic research partnership aimed at developing a new generation of masked…

Read More
Pharmaceutical R&D

Parabilis Medicines Aims for $475 Million Nasdaq IPO to Fund Pivotal Desmoid Tumour Trial and Pipeline Expansion

Teuku Ryan Jun 5, 2026 0

Parabilis Medicines, a biopharmaceutical company forging innovative therapeutic pathways, is charting a course for public market debut with a proposed…

Read More
Biotech Bi-Weekly Delivers Insight into Breakthrough Product Launches, Strategic Alliances, and Financial Shifts Shaping the IndustryAdvanced Blood Analysis of Immune Cell Aging Offers New Pathway for Objective Depression Diagnosis and Precision Mental Health CareMeningitis B Vaccine Expansion Under Consideration Amidst Kent OutbreakUnraveling the Deadly Secrets of Andes Hantavirus: A Path to Novel Treatments
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ